PhaseV is an AI-powered clinical development optimization platform that removes operational bottlenecks across the trial lifecycle, enabling faster and more efficient trials from design through execution. In use by 45+ sponsors, including 8 of the top 20 pharma, with representation in the top five, PhaseV is rapidly scaling across the industry.
PhaseV delivers value across the trial lifecycle through a suite of integrated modules, with AI Conductor at the core orchestrating all modules into a seamless, automated clinical decision workflow. It generates trial documents, statistical code, and data outputs in minutes, transforming processes that traditionally take weeks.
Users can optimize distinct aspects of the clinical workflow through plug-and-play modules, including:
- Trial Optimizer runs millions of simulations to generate optimized trial designs, including Bayesian, adaptive, or fixed designs, in minutes.
- ClinOps Optimizer aligns protocol criteria with real-world patient populations at the site level, enabling precision site selection and real-time monitoring.
- Portfolio Optimizer supports strategic decision-making, including what indications and combinations to pursue and in what sequence.
- Response Optimizer uncovers treatment heterogeneity, identifying the patient subgroups most likely to respond.
Across trial settings, PhaseV platform has demonstrated the ability to increase probability of success by more than 30%, reduce costs by approximately 50%, and shorten trial duration and enrollment requirements by up to 40%.